
Rachel Elliott
@rachelelliott67
Professor of Health Economics, member of NICE, part pharmacist, part health economist. Influences: Dosteovsky, Bowie, anyone vaguely original
ID: 40346501
15-05-2009 22:10:49
1,1K Tweet
477 Followers
353 Following









🚨 New 🔓 paper As part of RECOLLECT we investigated #RecoveryColleges across #England to determine organisational and student characteristics, #fidelity #funding, running costs, and developed a typology from these: bit.ly/3YPZfv2 HSPRD IOPPN Social Biobehavioural Research Group Behavioural Science & Health UCL


So you’re “bewildered & appalled” are you, Boris Johnson? Let me tell you what appals me. Your parties. Your quiz nights. Your brazen lies. Your champagne. You cavorted & boozed. While we watched patients in their 1000s - some of them our colleagues - die. You make me sick.


Our new report around medicines interoperability is published this week: research.manchester.ac.uk/en/publication… @PSRC_GM_ UoM Pharmacy and Optometry Manchester HealthEcon_MCR Rachel Elliott @RichardKeers Sean Gavan @e_camacho_phd Antony Chuter manchester.ac.uk/discover/news/…



I was thrilled to be a panelist in the discussion on the health economics and decision-analytic modeling of early cancer detection with such fantastic moderator and panelists, Larry Kessler, Beth Shinkins and Stuart Wright! #EDxConf23 Science and Innovation at Cancer Research UK Canary Center at Stanford OHSU Knight Cancer Institute


Celebrated the launch of the NIHR Greater Manchester Patient Safety Research Collaboration Rachel Elliott


The proudest moment of my professional life. To win #teamscirnce AACR 2024 is beyond amazing. I cannot thank Emma Crosbie, Prof Evan’s and the team everything. So proud to have impacted the care of #lynchsyndrome carriers. We do it for the patients. UoM Biology, Medicine and Health The Centre for Reproductive Health


The Lancet Delighted to have been part of the Lancet Commission on #ProstateCancer. Important it considered the challenge of making effective medicines affordable: “High drug costs are a major driving factor for disparities in prostate cancer outcomes”